You are currently viewing Gamida Cell Ltd closes today $40 million financing!

Jerusalem based Gamida Cell Ltd., a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that they have signed for $40 million financing to support the ongoing Phase 3 trial of the Company’s FDA Breakthrough Designated clinical-stage product, NiCord. NiCord facilitates bone marrow transplantation.

For more informations, see:

See Gamida Cell Ltd.’s site: